Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention (YARD-01)

A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Yangyin Qingfei Decoction in Preventing Radiation Pneumonitis

This prospective, randomized, controlled, open-label phase II clinical study will enroll patients with thoracic malignancies who are scheduled to receive thoracic radiotherapy and whose baseline chest CT/high-resolution CT (HRCT) shows no active pulmonary disease or prior radiation-induced lung injury that could interfere with the assessment of radiation pneumonitis (RP). Eligible patients will be randomized 1:1 to a treatment group or a control group. The control group will receive standard thoracic radiotherapy and routine supportive care; the treatment group will additionally receive oral Yangyin Qingfei Formula concurrently. Patients will be followed for 12 months after radiotherapy to evaluate the formula's efficacy, safety, and potential clinical translational value in preventing RP.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

230

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Department of Radiotherapy, The First Affiliated Hospital of Zhejiang Chinese Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  1. Age 18-80 years.
  2. A pathologically or cytologically confirmed thoracic malignancy, including lung cancer, esophageal cancer, thymic tumors, or similar tumors.
  3. Planned thoracic radiotherapy, with lung tissue expected to lie within the radiation field.
  4. No active pulmonary disease or prior radiation-induced lung injury on baseline chest CT/HRCT that could interfere with RP assessment.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  6. Estimated survival of at least 6 months.
  7. Blood counts: absolute neutrophil count >=3.0 x 10^9/L, platelets >=100 x 10^9/L, and hemoglobin >=90 g/L.
  8. Biochemistry: total bilirubin, blood urea nitrogen, and creatinine <=1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase <=2 times the ULN.
  9. Ability to eat normally and take a Chinese herbal decoction; voluntary participation and written informed consent.

Exclusion criteria

  1. Baseline chest CT/HRCT showing active pulmonary infection, interstitial lung disease, marked pulmonary fibrosis, immunotherapy-related pneumonitis, tumor-related post-obstructive pneumonia, or another pulmonary condition that could interfere with RP assessment.
  2. Unequivocal tumor progression according to RECIST 1.1, or an investigator's judgment that radiotherapy and follow-up cannot be completed in the near term.
  3. Severe hepatic, renal, cardiovascular, gastrointestinal, or metabolic disease that could affect the safety or efficacy assessment of the study treatment.
  4. Pregnancy or breastfeeding, or a severe psychiatric disorder that prevents cooperation with the study.
  5. Participation in another interventional clinical trial within the previous 3 months.
  6. Regular use of other Chinese herbal medicines, Chinese patent medicines, or antifibrotic drugs specifically intended to prevent RP.
  7. Poor adherence, inability to take the herbal decoction regularly, or inability to complete scheduled follow-up.
  8. Any other condition judged by the investigator to make the patient unsuitable for enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Yangyin Qingfei Formula plus standard thoracic radiotherapy and routine supportive care

Yangyin Qingfei decoction will contain Tai Zi Shen (Pseudostellariae Radix) 15 g, Mai Dong (Ophiopogonis Radix) 15 g, Tian Dong (Asparagi Radix) 15 g, Nan Sha Shen (Adenophorae Radix) 15 g, Bei Sha Shen (Glehniae Radix) 15 g, Huang Qin (Scutellariae Radix) 15 g, and Jiao Shan Zhi (charred Gardeniae Fructus) 9 g. One daily prescription will be administered in two doses, 200 mL per dose. If grade 1 gastrointestinal discomfort or another adverse reaction judged possibly related to the decoction occurs, the dose may be reduced to 100 mL twice daily and restored to 200 mL twice daily after symptoms resolve. For grade 2 adverse reactions, the decoction may be suspended and symptomatic treatment provided; after recovery to grade 0-1, treatment may be resumed, with or without dose reduction, at the investigator's discretion. If a grade >=3 adverse reaction, a serious adverse event, or clinically significant decoction-related intolerance occurs, decoction treatment should be stopped, with the r

Active Comparator: Standard thoracic radiotherapy plus routine supportive care

Standard thoracic radiotherapy plus routine supportive care

The control group will receive standard thoracic radiotherapy and routine supportive care without Yangyin Qingfei decoction. Supportive care includes nutritional support and symptomatic management, such as cough relief, expectoration, relief of wheezing, and anti-infective treatment when necessary. Chemotherapy, targeted therapy, or immunotherapy may be administered during follow-up at the investigator's discretion, under the same principles as in the treatment group. Prophylactic amifostine, nintedanib, or other antifibrotic drugs will not be used routinely, nor will other Chinese herbal medicines, Chinese patent medicines, or health supplements specifically intended to prevent RP be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of grade >=2 RP
Time Frame: 3 months after radiotherapy completion
3 months after radiotherapy completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: chao chen, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 20, 2026

Primary Completion (Estimated)

June 1, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2027-KS-133-01
  • 2027117845 (Other Grant/Funding Number: 2027 Annual Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

De-identified individual participant data will not be publicly released. Data may be available from the principal investigator upon reasonable request with a formal data-use agreement

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.